Adam Davenport is Chief Scientific Officer at Concept Life Sciences, where he leads scientific strategy, innovation, and the integration of capabilities to support clients from early discovery through development.

Adam brings more than 25 years of global drug discovery leadership experience across biotech and CRO environments. Prior to joining Concept Life Sciences, he served as Chief Discovery Officer at Proxygen GmbH and Chief R&D Officer at Dalriada Drug Discovery, leading oncology-focused targeted protein degradation programs and building high-impact discovery capabilities.

Previously, Adam spent over two decades at Evotec, progressing multiple programs from discovery to clinical evaluation across diverse modalities and therapeutic areas. He is the lead inventor of several Phase 2 clinical assets and has authored more than 60 patents and scientific publications. Adam holds a BSc (Hons) in Chemistry and a PhD in Organometallic Chemistry from the University of Leicester, UK.

‍